Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
22.66
-0.18 (-0.79%)
Nov 5, 2024, 1:21 PM EST - Market open
Viridian Therapeutics Employees
Viridian Therapeutics had 94 employees as of December 31, 2023. The number of employees increased by 8 or 9.30% compared to the previous year.
Employees
94
Change (1Y)
8
Growth (1Y)
9.30%
Revenue / Employee
$3,064
Profits / Employee
-$2,426,117
Market Cap
1.73B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Myriad Genetics | 2,700 |
NovoCure | 1,453 |
Certara | 1,391 |
AtriCure | 1,200 |
BioCryst Pharmaceuticals | 536 |
Kiniksa Pharmaceuticals International, | 297 |
Nurix Therapeutics | 284 |
Ocular Therapeutix | 267 |
VRDN News
- 12 days ago - Viridian Therapeutics' Superior Prospects Make It A Buy - Seeking Alpha
- 6 weeks ago - 3 Small Biotech Stocks With The 'Big Mo' Right Now - Seeking Alpha
- 7 weeks ago - Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock - Business Wire
- 7 weeks ago - Viridian: Active TED Data Signifies Next Round Of Positive Data On The Way - Seeking Alpha
- 7 weeks ago - Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock - Business Wire
- 2 months ago - Viridian Therapeutics' eye disorder treatment meets main goal in late-stage study - Reuters
- 2 months ago - Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease - Business Wire
- 2 months ago - Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024 - Business Wire